Welcome to our dedicated page for Lunai Bioworks SEC filings (Ticker: LNAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lunai Bioworks Inc. (NASDAQ: LNAI) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As an AI-powered drug discovery and biodefense company in the pharmaceutical preparations sector, Lunai uses these filings to report on capital markets activity, risk factors, and material events related to its AI platforms, therapeutic programs, and corporate structure.
Core documents such as annual reports on Form 10-K and quarterly reports on Form 10-Q contain narrative and financial information about Lunai’s operations, including its Augusta platform, the activities of its BioSymetrics subsidiary, and development efforts in areas such as allogeneic dendritic cell therapy, neurodegenerative disease research, biomarker discovery, and biodefense-oriented neurotoxicity screening. These reports also present detailed risk factor discussions and management’s analysis of the company’s strategy and operating environment.
Current reports on Form 8-K highlight specific material events. For example, Lunai has filed an 8-K describing a private placement of common stock and warrants to an accredited investor under exemptions from registration, outlining the terms of the securities purchase agreement, resale restrictions, and reliance on Section 4(a)(2) and Rule 506(b) of Regulation D. Similar filings can disclose stock splits, listing compliance developments, corporate identity changes, or other significant corporate actions.
Investors can also review registration statements, proxy materials, and, where applicable, insider transaction reports on Form 4 to understand equity ownership changes by directors and officers. Stock Titan enhances access to these documents with AI-powered summaries that explain key points from lengthy filings, highlight notable changes, and help readers navigate complex legal and technical language. Real-time updates from EDGAR ensure that new Lunai Bioworks filings, including 10-K, 10-Q, 8-K, and Form 4 submissions, are available promptly for analysis.
Lunai Bioworks, Inc. entered into a private placement with an accredited investor to sell 3,133,333 common shares at $1.00 per share, together with 1,044,444 three-year warrants exercisable after 60 days, for aggregate gross proceeds of $3,133,333. The transaction relies on exemptions from registration under Section 4(a)(2) and Rule 506(b), involves no underwriting discounts or commissions, and the securities are subject to resale restrictions under Rule 144. The terms are governed by a securities purchase agreement that includes customary representations, warranties, and covenants.
FAQ
What is the current stock price of Lunai Bioworks (LNAI)?
What is the market cap of Lunai Bioworks (LNAI)?
